Raynaud’s phenomenon (syndrome) in neurological disorders
Keywords:
Raynaud’s phenomenon, neurological disorders, prevalence, treatmentAbstract
Raynaud’s phenomenon is a vasospastic disorder characterized by sudden, well distinguishable pallor and subsequently cyanosis and redness of fingers, toes, less frequently of nose and ears, accompanied by pain and numbness. It may appear as standalone symptom (Raynaud’s disease) or in course of other disease as an accompanying symptom (Raynaud’s syndrome). In most cases Raynaud’s phenomenon accompanies connective tissue disorders, but it is also often seen during neurological illness. It is never, however, a dominant symptom. It may be the first symptom to appear and precedes full-blown disease (Sneddon’s syndrome, multiple system atrophy, polymyositis) or it may occur during the whole course of the disease (migraine). It is usually present during long-lasting diseases (syringomyelia, multiple sclerosis, carpal tunnel syndrome, thoracic outlet syndrome). The clinical picture is distinct and diagnosis can be made on basis of a well-conducted assessment of medical history. Management of Raynaud’s phenomenon includes treatment of the primary disease as well as treatment of vessel constriction. Surgical treatment is rarely advised and then only in cases of trophic changes and severely advanced symptoms.
Downloads
References
Wigley FM. Clinical practice: Raynaud’s phenomenon. N Engl J Med 2002;347:1001–1008.
Cooke J.P., Marshal J.M.: Mechanisms of Raynaud’s disease. Vasc Med 2005;10:293–307.
Boin F, Wigley FM. Understanding, assessing and treating Raynaud’s phenomenon. Curr Opin Rheumatol 2005;17:752–760.
Bakst R, Merola JF, Franks AG, Sanchez M. Raynaud’s phenomenon: pathogenesis and management. J Am Acad Dermatol. 2008;59(4):633–653.
Herrick AL. Patogenesis of Raynaud’s phenomenon. Rheumatol 2005;44: 587–596.
Baumhäkel M, Böhm M. Recent achievements in the management of Raynaud’s phe-nomenon. Vasc Health Risk Manag. 2010;6:207–214.
Gerbracht DD, Steen VD, Ziegler GL, Medsger TA Jr, Rodnan GP. Evolution of pri-mary Raynaud's phenomenon (Raynaud's disease) to connective tissue disease. Arthri-tis Rheum 1985;28:87-92 .
Atkinson RA, Appenzeller O. Hemicrania and Raynaud's phenomenon; manifestations of the same disease ? Headache. 1976;16(1):1-3.
Zahavi I, Chagnac A, Hering R, Davidovich S, Kuritzky A. Prevalence of Raynaud's phenomenon in patients with migraine. Arch Intern Med. 1984;144(4):742-4.
O'Keeffe ST, Tsapatsaris NP, Beetham WP Jr. Increased prevalence of migraine and chest pain in patients with primary Raynaud disease. Ann Intern Med. 1992;116:985-9.
O'Keeffe ST, Tsapatsaris NP, Beetham WP Jr. Association between Raynaud's phe-nomenon and migraine in a random population of hospital employees. J Rheumatol. 1993;20: 1187-8.
Miller D, Waters DD, Warnica W, Szlachcic J, Kreeft J, Théroux P. Is variant angina the coronary manifestation of a generalized vasospastic disorder ? N Engl J Med. 1981;304: 763-6.
Leppert J, Aberg H, Ringqvist I, Sörensson S. Raynaud's phenomenon in a female population: prevalence and association with other conditions. Angiology. 1987;38(12):871-7.
Terwindt GM, Haan J, Ophoff RA, Groenen SM, Storimans CW, Lanser JB i wsp. Clinical and genetic analysis of a large Dutch family with autosomal dominant vascu-lar retinopathy, migraine and Raynaud's phenomenon. Brain. 1998;121:303-16.
Isenberg DA, Meyrick-Thomas D, Snaith ML, McKeran RO, Royston JP. A study of migraine in systemic lupus erythematosus. Ann Rheum Dis. 1982 Feb;41(1):30-2.
Pal B, Gibson C, Passmore J, Griffiths ID, Dick WC. A study of headaches and mi-graine in Sjögren's syndrome and other rheumatic disorders. Ann Rheum Dis. 1989;48(4):312-6.
Kallenberg CG, Wouda AA, The TH. Systemic involvement and immunological find-ings in patients presenting with Raynaud's phenomenon. Am J Med, 1980;69:675.
Sneddon IB. Cerebrovascular lesions and livedo reticularis. Br J Dermatol 1965;77:180-185.
Marinho JL, Piovesan EJ, Leite Neto MP, Kotze LR, Noronha L, Twardowschy CA i wsp. Clinical, neurovascular and neuropathological features in Sneddon's syndrome. Arq Neuropsiquiatr. 2007;65:390-5.
Hilton DA, Footitt D. Neuropathological findings in Sneddon´s syndrome. Neurology 2003;60:1181-1182.
Schlez A, Lischka G, Schaumburg-Lever G, Ganten T, Jünger M. Raynaud symptoms as principal signs in a case of Sneddon's syndrome. J Eur Acad Dermatol Venereol. 2001;15: 365-6.
Flöel A, Imai T, Lohmann H, Bethke F, Sunderkötter C, Droste DW. Therapy of Sneddon's syndrome. Eur Neurol 2002;48:126-132.
Karagülle AT, Karadag D, Erden A, Erden I. Sneddon´s syndrome: MR imaging find-ings. Eur Radiol 2002;12:144-146.
Majewski D, Puszczewicz M, Kołczewska A. Diagnostyka różnicowa zapalenia mię-śni – opis przypadku. Ann Acad Med Stetin. 2010;56(Suppl.1):66–69.
Mielnik P. Immunological abnormalities in patients with polymyositis and dermato-myositis. Ann Rheum Dis 2005;64(Suppl.3):255.
Marie I, Lahaxe L, Benveniste O, Delavigne K, Adoue D, Mouthon L i wsp. Long-term outcome of patients with polymyositis/ dermatomyositis and anti-PM-Scl anti-body. Br J Dermatol. 2010;162(2):337-44.
Jaskólski D. Zespoły objawowe powstałe z uwięźnięcia. W: Kozubski W, Liberski P, red. Choroby układu nerwowego. PZWL; 2004: 505-6.
Chung MS, Gong HS, Baek GH. Prevalence of Raynaud's phenomenon in patients with idiopathic carpal tunnel syndrome. J Bone Joint Surg Br. 1999;81(6):1017-9.
Chung MS, Gong HS, Baek GH. Raynaud's phenomenon in idiopathic carpal tunnel syndrome: postoperative alteration in its prevalence. J Bone Joint Surg Br. 2000;82:818-9.
Pistorius MA, Planchon B. Incidence of thoracic outlet syndrome on the epidemiology and clinical presentation of apparently primary Raynaud's phenomenon. A prospective study in 570 patients. Int Angiol. 1995;14(1):60-4.
Nichols AW. Diagnosis and management of thoracic outlet syndrome. Curr Sports Med Rep. 2009;8(5):240-9.
Boezaart AP, Haller A, Laduzenski S, Koyyalamudi VB, Ihnatsenka B, Wright T. Neurogenic thoracic outlet syndrome: A case report and review of the literature. Int J Shoulder Surg. 2010; 4(2):27-35.
Onder M, Ozden MG, Aksakal AB, Akçali D, Babacan A, Atasever T. Raynaud phe-nomenon and Behçet disease: diagnosis with technetium Tc 99m methylene diphos-phonate bone scan and treatment with continuous sympathetic block. Arch Dermatol. 2002;138:698-9.
Hiller N, Lieberman S, Chajek-Shaul T, Bar-Ziv J, Shaham D. Thoracic manifesta-tions of Behçet disease at CT. Radiographics. 2004;24(3):801-8.
Evereklioglu C. Current concepts in the etiology and treatment of Behçet disease. Surv Ophthalmol. 2005 ;50(4):297-350.
Cruz BA, Queiroz ED, Nunes SV, Cruz Filho A, Campos GB, Monteiro EL, Crivellari H. Severe Raynaud's phenomenon associated with interferon-beta therapy for multiple sclerosis: case report. Arq Neuropsiquiatr. 2000;58:556-9.
Bachmeyer C, Farge D, Gluckman E, Miclea JM, Aractingi S. Raynaud’s phenome-non and digital necrosis induced by interferon-alpha. Br J Dermatol 1996;135:481-483.
Linden D. Severe Raynaud's phenomenon associated with interferon-b treatment for multiple sclerosis [Letter]. Lancet 1998;352:878-879.
De Broucker T, Lhote F. Severe Raynaud's phenomenon associated with interferon-beta 1a and fluoxetine. Ann Med Interne (Paris). 2000;151(5):424-5.
Rudnick A, Modai I, Zelikovski A. Fluoxetine-induced Raynaud's phenomenon. Biol Psychiatry. 1997;41:1218-21.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2013 Medical Journal of the Rzeszow University and the National Medicines Institute, Warsaw
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
